Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Primary relevance to vitamin D Vitamin D is a stated subject of this paper.

Vitamin D is a stated subject of this paper; the supporting source evidence is shown below.

Why this paper is included

Supporting source evidence:

The aim was to assess the effects of vitamin D supplementation on relapse in patients with digestive tract cancer showing an immune response in the tumor.

Source: Abstract. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Secondary analysis.

Secondary analysis

Analyses existing study data; this paper is not automatically another independent trial.

Meta-analysis unclear · Double-blind reported · Human research reported

Reported blinded roles: investigators.

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

Effect of Vitamin D Supplements on Relapse of Digestive Tract Cancer with Tumor Stromal Immune Response: A Secondary Analysis of the AMATERASU Randomized Clinical Trial

Source: Article title.

A secondary analysis of a randomized clinical trial including 372 patients was performed.

Source: Abstract.

Briefly, the parent trial enrolled 417 patients with digestive tract cancers from the esophagus to the rectum who participated in a randomized, double-blind, placebo-controlled trial to compare the effects of vitamin D3 supplements (2000 IU/day) and placebo on relapse and/or death at an allocation ratio of 3:2 at the International University of Health and Welfare Hospital (Otawara, Tochigi, Japan) between January 2010 and February 2018.

Source: Methods.

All image analysis procedures were performed by the investigators (TA, KK), who were blind to the randomized groups and clinical information, including outcomes, and fixed prior to statistical analyses.

Source: Methods.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Effect of Vitamin D Supplements on Relapse of Digestive Tract Cancer with Tumor Stromal Immune Response: A Secondary Analysis of the AMATERASU Randomized Clinical Trial

Secondary analysis · Cancers · 2021

Original publication title

Effect of Vitamin D Supplements on Relapse of Digestive Tract Cancer with Tumor Stromal Immune Response: A Secondary Analysis of the AMATERASU Randomized Clinical Trial

Taisuke Akutsu; Kazuki Kanno; Shinya Okada; Hironori Ohdaira; Yutaka Suzuki; Mitsuyoshi Urashima

© 2021 by the authors.

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

At a glance

Abstract: Simple Summary

Clinical evidence suggesting the beneficial effects of vitamin D supplementation on survival of patients with cancer has been accumulating. More tumoral immune cells have been shown to be associated with a longer survival time; however, interactions among vitamin D supplementation, intratumoral immune cells, and cancer relapse have not yet been elucidated. The aim was to assess the effects of vitamin D supplementation on relapse in patients with digestive tract cancer showing an immune response in the tumor. A secondary analysis of a randomized clinical trial including 372 patients was performed.

In the higher half subgroup of CD56+ immune cells infiltrating in tumor stroma, the relapse ratio was significantly lower in the vitamin D group (7.4%), than in the placebo group (20.5%), whereas in the lower half subgroup, relapse ratio was not different. Vitamin D supplementation may reduce the risk of relapse in patients who already had adequate infiltration of immune cells in their tumor stroma.

Source: Simple Summary

Abstract: Abstract

The aim was to examine whether vitamin D supplementation (2000 IU/day) reduces the risk of relapse in a subgroup of patients with digestive tract cancer, showing a sufficient immune response in tumor stroma by conducting secondary subgroup analyses of the AMATERASU randomized, double-blind, placebo-controlled trial (UMIN000001977). A total of 372 patients were divided into two subgroups stratified by the median density of immune cells infiltrating in tumor stroma into higher and lower halves. In the higher-half subgroup of CD56+ cells, the relapse ratio was significantly lower in the vitamin D group (7.4%) than in the placebo group (20.5%) (subdistribution hazard ratio (SHR), 0.35; 95% confidence interval (CI), 0.15 to 0.82), but it was equivalent (25.2% vs. 22.7%) in the lower-half subgroup of CD56+ cells (SHR, 1.21; 95% CI, 0.68 to 2.19) with a significant interaction (Pinteraction = 0.02).

Although there were no significant differences, the risk of relapse was lower in the vitamin D group than in the placebo group in the higher half of CD45RO+ memory T cells (8.9% vs. 19.2%), and of CD8+ cytotoxic T cells (11.3% vs. 22.5%). In patients with digestive tract cancer, vitamin D supplementation was hypothesized to reduce the risk of relapse in the subgroup of patients who already have an adequate infiltration of immune cells in their tumor stroma.

Source: Abstract
Authors’ abstract

Simple Summary

Clinical evidence suggesting the beneficial effects of vitamin D supplementation on survival of patients with cancer has been accumulating. More tumoral immune cells have been shown to be associated with a longer survival time; however, interactions among vitamin D supplementation, intratumoral immune cells, and cancer relapse have not yet been elucidated. The aim was to assess the effects of vitamin D supplementation on relapse in patients with digestive tract cancer showing an immune response in the tumor. A secondary analysis of a randomized clinical trial including 372 patients was performed.

In the higher half subgroup of CD56+ immune cells infiltrating in tumor stroma, the relapse ratio was significantly lower in the vitamin D group (7.4%), than in the placebo group (20.5%), whereas in the lower half subgroup, relapse ratio was not different. Vitamin D supplementation may reduce the risk of relapse in patients who already had adequate infiltration of immune cells in their tumor stroma.

Abstract

The aim was to examine whether vitamin D supplementation (2000 IU/day) reduces the risk of relapse in a subgroup of patients with digestive tract cancer, showing a sufficient immune response in tumor stroma by conducting secondary subgroup analyses of the AMATERASU randomized, double-blind, placebo-controlled trial (UMIN000001977). A total of 372 patients were divided into two subgroups stratified by the median density of immune cells infiltrating in tumor stroma into higher and lower halves. In the higher-half subgroup of CD56+ cells, the relapse ratio was significantly lower in the vitamin D group (7.4%) than in the placebo group (20.5%) (subdistribution hazard ratio (SHR), 0.35; 95% confidence interval (CI), 0.15 to 0.82), but it was equivalent (25.2% vs. 22.7%) in the lower-half subgroup of CD56+ cells (SHR, 1.21; 95% CI, 0.68 to 2.19) with a significant interaction (Pinteraction = 0.02).

Although there were no significant differences, the risk of relapse was lower in the vitamin D group than in the placebo group in the higher half of CD45RO+ memory T cells (8.9% vs. 19.2%), and of CD8+ cytotoxic T cells (11.3% vs. 22.5%). In patients with digestive tract cancer, vitamin D supplementation was hypothesized to reduce the risk of relapse in the subgroup of patients who already have an adequate infiltration of immune cells in their tumor stroma.

Publication and source details

Original title: Effect of Vitamin D Supplements on Relapse of Digestive Tract Cancer with Tumor Stromal Immune Response: A Secondary Analysis of the AMATERASU Randomized Clinical Trial

Taisuke Akutsu; Kazuki Kanno; Shinya Okada; Hironori Ohdaira; Yutaka Suzuki; Mitsuyoshi Urashima

Cancers · 2021

* Correspondence: urashima.mitsu@gmail.com; Tel.: +81-3-3433-1111
†

These authors contributed equally to this article.

© 2021 by the authors.2021https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-11T12:05:34.389115+00:00

DOI: 10.3390/cancers13184708 · PMC8470811